Cargando…
Subcutaneous Immunoglobulins are a Valuable Treatment Option in Myasthenia Gravis
Autores principales: | Garnero, Martina, Fabbri, Sabrina, Gemelli, Chiara, Benedetti, Luana, Mancardi, Giovanni Luigi, Schenone, Angelo, Grandis, Marina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Neurological Association
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5765263/ https://www.ncbi.nlm.nih.gov/pubmed/29141277 http://dx.doi.org/10.3988/jcn.2018.14.1.98 |
Ejemplares similares
-
Comparing the Impact of COVID-19 on Vaccinated and Unvaccinated Patients Affected by Myasthenia Gravis
por: Scarsi, Elena, et al.
Publicado: (2023) -
Long-term treatment of refractory myasthenia gravis with subcutaneous immunoglobulin
por: Kovács, Edina, et al.
Publicado: (2017) -
Subcutaneous Immunoglobulin Therapy in the Chronic Management of Myasthenia Gravis: A Retrospective Cohort Study
por: Bourque, P. R., et al.
Publicado: (2016) -
Usefulness of subcutaneous immunoglobulin therapy in the management of myasthenia gravis: a retrospective cohort study
por: Barnay, Marlène, et al.
Publicado: (2022) -
Pharmacodynamic Properties of Subcutaneous Immunoglobulin in Myasthenia Gravis: Sub-analyses From an Open-Label Trial
por: Putko, Brendan N., et al.
Publicado: (2020)